English
Home > Products > 863329-66-2

China 863329-66-2 Factory

Each individual member from our large performance revenue crew values customers' requirements and organization communication for 863329-66-2,CAS NO 863329-66-2,Sofosbuvir intermediate,Sofosbuvir advance intermediate,2'-deoxy-2'-fluoro-, Trust us and you will gain a lot more. You should truly feel totally free to make contact with us for additional data, we assure you of our greatest notice at all times.
863329-66-2, For many years, we have now adhered to the principle of customer oriented, quality based, excellence pursuing, mutual benefit sharing. We hope, with great sincerity and good will, to have the honor to help with your further market.

Related Products

Hot Products

  • Resmetirom

    Resmetirom

    Product Name:Resmetirom
    Molecular Formula:C17H12Cl2N6O4
    Molecular Weight;435.22
    CAS Registry Number;920509-32-6
  • Ademetionine 1,4-butanedisulfonate

    Ademetionine 1,4-butanedisulfonate

    Product Name:Ademetionine 1,4-butanedisulfonate
    Molecular Formula:C23H41N6O17S5-
    Molecular Weight:833.91
    CAS Registry Number:101020-79-5
  • 4-Cloromethyl-5-methyl-1,3-dioxol-2-one

    4-Cloromethyl-5-methyl-1,3-dioxol-2-one

    Product Name:4-Cloromethyl-5-methyl-1,3-dioxol-2-one
    Molecular Formula:C5H5ClO3
    Molecular Weight:148.54
    CAS Registry Number:80841-78-7
  • 4-Chloro-alpha,alpha,alpha-trifluoro-m-toluidine

    4-Chloro-alpha,alpha,alpha-trifluoro-m-toluidine

    Product Name:4-Chloro-alpha,alpha,alpha-trifluoro-m-toluidine
    Molecular Formula:C7H5ClF3N
    Molecular Weight:195.57
    CAS Registry Number:320-51-4
  • 2-Amino-3-(trifluoromethyl)pyridine

    2-Amino-3-(trifluoromethyl)pyridine

    Product Name:2-Amino-3-(trifluoromethyl)pyridine
    Molecular Formula:C6H5F3N2
    Molecular Weight:162.11
    CAS Registry Number:183610-70-0
  • Tiotropium bromide

    Tiotropium bromide

    Product Name:Tiotropium bromide
    Molecular Formula:C19H22BrNO4S2
    Molecular Weight;472.42
    CAS Registry Number;136310-93-5
  • Related Blog
  • Reviews

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • How is a drug produced?

    ​There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 863329-66-2

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept